Impact of probiotic supplementation on kidney transplantation outcomes:a retrospective propensity score matched study
- Author:
Yookyung JANG
1
;
Tai Yeon KOO
;
Young-Eun CHOI
;
Cheol Woong JUNG
;
Young Ju OH
;
Heungman JUN
;
Sewon OH
;
Sang-Kyung JO
;
Myung-Gyu KIM
Author Information
- Publication Type:Original Article
- From: Clinical Transplantation and Research 2025;39(4):335-345
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The potential benefits and risks of probiotic use in kidney transplant (KT) recipients remain unclear. This study aimed to evaluate the effects of probiotic supplementation on KT outcomes.
Methods:A retrospective analysis was performed using medical records from 354 KT recipients between January 2010 and December 2020. Only patients who received probiotics within the first year following transplantation were included, and transplant outcomes were assessed at 1–3 years after KT.
Results:Among the 354 patients, 97 (27%) received probiotics during the study period, and 36 (10%) used them for more than 3 months. Probiotic types included Lactobacillus species (45.4%), Bacillus subtilis (14.4%), and others (40.2%). The average supplementation duration was 104.8 days. No significant differences in estimated glomerular filtration rate at 1 and 3 years posttransplantation were observed between the probiotic and nonprobiotic groups. Cytomegalovirus (CMV) viremia developed in 61 patients, with a significantly higher incidence observed in the probiotic group (25.8% vs. 14.0%).However, there were no significant differences in BK viremia or coronavirus disease 2019 infection rates between groups. During the study period, 116 patients received antibiotics for more than 1 week, and the prevalence of bacterial infections was not significantly different between the two groups. After propensity score matching, probiotic supplementation remained significantly associated only with the development of CMV viremia.
Conclusions:This study identified a significant association between probiotic use and the occurrence of CMV viremia in KT recipients. To better define the safety and efficacy of probiotics in immunocompromised patients, large-scale prospective studies are necessary to establish comprehensive evidence.
